Refractory Follicular Lymphoma

Refractory Follicular Lymphoma is the indication for 13 drugs in DrugBank. It is covered by 19 curated, structured indications.

Also known as: Lymphoma, B-Cell Refractory · B-cell Lymphoma Refractory · refractory Lymphoma, B-Cell · refractory B-Cell Lymphoma · Follicular Lymphoma-Refractory
Classified under: Hemic and Lymphatic Diseases
Neoplasms
Indicated drugs: Axicabtagene ciloleucel
Epcoritamab
Hyaluronidase (ovine)
Lenalidomide
Lisocabtagene maraleucel
Mosunetuzumab
Obinutuzumab
Odronextamab
Rituximab
Tafasitamab
Tazemetostat
Tisagenlecleucel
Zanubrutinib

Resolves to

Vocabularies

MedDRA10003903UMLSC0855090

What you can answer from here — as of October 06, 2026

13Indicated drugsWith each drug's targets and mechanism

Listed above

19Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

169Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Refractory Follicular Lymphoma share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.